Adaptimmune (ADAP): Price-to-Revenue Ratio

Symbol and logo of brand Adaptimmune (ADAP)

Is it worth investing in the cancer-fighting biotech sector? The answer is provided by the smoothed P/S chart for Adaptimmune (ADAP) from GURU.Markets, where the value 0.20 describes the current level. Adaptimmune (ADAP) is implementing energy-saving measures for biosample storage and strict security regulations. Therapy development relies on international bioethics and data protection. Flawless logistics guarantee the express delivery of cells without delays.

ADAP: Adaptimmune Therapeutics P/S Multiple 07/04/2022 - 11/01/2025

Metric breakdowns and analytics for Adaptimmune (ADAP)

- current price and projected stock value:
Price Chart adaptimmune.com|ADAP - Price Target Chart
- stock exchange capitalization data:
Market Value Adaptimmune|ADAP - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share Adaptimmune Therapeutics|ADAP - Book Capitalization|Market Value to Equity Ratio adaptimmune.com|ADAP - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Adaptimmune|ADAP - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio adaptimmune.com|ADAP - Company Aggregate Debts|Debts to Book Value Adaptimmune|ADAP - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Adaptimmune Therapeutics|Intermediate Liquidity Ratio adaptimmune.com
- earnings and valuation multiples information:
ADAP - Net Profit|Expected Net Income Adaptimmune|ADAP - P/E Multiple|Projected Price to Earnings Ratio adaptimmune.com|ADAP - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Adaptimmune|ADAP - Operating profit EBITDA|Net earnings per share (EPS TTM) Adaptimmune Therapeutics|ADAP - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months adaptimmune.com|ADAP - Net earnings per share growth this year|Expected net earnings per share growth next year Adaptimmune
- issuer revenue and sales details:
ADAP - Revenue and Sales Volume|Projected Sales Volume adaptimmune.com|ADAP - P/S Multiple|Market Cap to Projected Revenue Adaptimmune
General company analysis:ADAP - Adaptimmune Therapeutics plc
Mass-produced product of Adaptimmune Therapeutics plc

The reliability of equity assets is assessed by comparing the market value of a business with its actual cash flows. The P/S ratio measures the cost of a single unit of revenue, determining the extent to which an investor is overpaying for current sales. For Adaptimmune (ADAP) and its innovative T-cell therapy for solid tumors, this calculation reflects market expectations for future breakthroughs in oncology. An analysis of the company's smoothed P/S allows for the separation of speculative noise from fundamental value.

Who Adaptimmune competes with

Price-to-Revenue Ratio LEGN (legendbiotech.com)|Price-to-Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RNAC (Selecta Biosciences Inc.)|CLLS: P/S Multiple|Price-to-Revenue Multiple cariboubio.com CRBU|TIL (Instil Bio) - P/S Multiple|Price to Sales Genenta GNTA|Price-to-Revenue Ratio Century Therapeutics (IPSC)|jaspertherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple SNTI (Senti Biosciences)|CERo Therapeutics Holdings, Inc. (CERO) - Price to Sales|TCRT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACHL (Achilles Therapeutics)|CRGX (Cargo Therapeutics) - Market Cap to Revenue|PSTX: Market Cap to Sales Volume|TSVT (2seventy bio, Inc.) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio